Drug Profile
Research programme: immuno-oncology therapeutics - Jiangsu Hengrui Medicine/ University of Texas MD Anderson Cancer Center
Latest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.; University of Texas M. D. Anderson Cancer Center
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer